Tomato-based functional food as interferon adjuvant in HCV eradication therapy

被引:12
|
作者
Morisco, F [1 ]
Vitaglione, P
Carbone, A
Stingo, S
Scarpati, S
Ascione, A
Marmo, R
Fogliano, V
Nicola, C
机构
[1] Univ Naples Federico II, Dept Food Sci, I-80055 Naples, Italy
[2] Cardarelli Hosp, Hepatol Unit, Naples, Italy
[3] Polla Hosp, Salerno, Italy
关键词
chronic hepatitis C; ribavirin; pegylated interferon; oxidative stress; functional foods;
D O I
10.1097/01.mcg.0000128935.48082.f9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Goals: The authors conducted a study to verify whether supplementation with an antioxidant-rich tomato-based functional food reduces anemia during pegylated interferon and ribavirin therapy for chronic hepatitis C. Background: Oxidative stress plays a major role in the physiopathology of hemolytic anemia during ribavirin therapy. The efficacy of antioxidant supplementation with vitamins C and E as pure compounds, is still controversial. Methods: A functional food with a high content of natural antioxidants and with high carotenoid bioavailability was developed. The authors enrolled 92 patients with chronic hepatitis C, treated with standard combination therapy. Forty-six of them received a daily dose (100 g) of functional food (group 1), and 46 did not (group 2). The effect of antioxidant activity was assessed comparing compliance with the full dose of ribavirin and hemoglobin levels during the first 3 months of treatment. Results: Only 8.7% of patients in group 1 had to reduce their daily ribavirin dose, whereas ribavirin reduction was necessary for 30.4% of patients in group 2 (P = 0.09). Hemoglobin levels showed significant differences at 15, 30, and 90 days during the observation time. Conclusion: Results demonstrated that the authors' functional food reduces the severity of ribavirin-related anemia and improves the tolerance to the full dose of ribavirin in patients with chronic hepatitis C.
引用
收藏
页码:S118 / S120
页数:3
相关论文
共 50 条
  • [41] Insulin resistance: A predictor for response to interferon-based therapy in Egyptian patients with chronic HCV genotype 4
    Mogawer S.
    Mansour M.
    Marie M.
    El-Ansary M.
    El-Hamid S.A.
    Comparative Clinical Pathology, 2014, 23 (1) : 7 - 13
  • [42] The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
    Nagaoki, Yuko
    Imamura, Michio
    Aikata, Hiroshi
    Daijo, Kana
    Teraoka, Yuji
    Honda, Fumi
    Nakamura, Yuki
    Hatooka, Masahiro
    Morio, Reona
    Morio, Kei
    Kan, Hiromi
    Fujino, Hatsue
    Kobayashi, Tomoki
    Masaki, Keiichi
    Ono, Atsushi
    Nakahara, Takashi
    Kawaoka, Tomokazu
    Tsuge, Masataka
    Hiramatsu, Akira
    Kawakami, Yoshiiku
    Hayes, C. Nelson
    Miki, Daiki
    Ochi, Hidenori
    Chayama, Kazuaki
    PLOS ONE, 2017, 12 (08):
  • [43] Clinico-immunological outcomes of HCV-cured cryoglobulinemia: Lower relapse rate with interferon-based than interferon-free therapy
    Colantuono, Stefania
    Marrapodi, Ramona
    Del Padre, Martina
    Collalti, Giulia
    Garzi, Giulia
    De Santis, Adriano
    Fiorilli, Massimo
    Basili, Stefania
    Visentini, Marcella
    Casato, Milvia
    LIVER INTERNATIONAL, 2021, 41 (01) : 70 - 75
  • [44] Regression of fibrosis in interferon-free sofosbuvir-based anti-HCV therapy after liver transplantation
    Seifert, Leon L.
    Vorona, Elena
    Schmidt, Hartmut H.
    HEPATOLOGY, 2014, 60 (06) : 1277A - 1277A
  • [45] Association of TLR7 polymorphisms with response to interferon-alpha-based therapy in patients with chronic hcv infection
    Schott, E.
    Witt, H.
    Weich, V.
    Halangk, J.
    Bergk, A.
    Wiedenmann, B.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S176 - S176
  • [46] Development of Combination Therapy of Bifidobacterium-Based Oral Vaccine Displaying HCV-NS3 with Interferon-α
    Kitagawa, Koichi
    Ishikawa, Hiroki
    Oda, Tsugumi
    Saito, Hiroki
    Morishita, Naoya
    Shimamoto, Kouske
    Nishida, Norihisa
    Matsuura, Yoichi
    Hotta, Hak
    Shirakawa, Toshiro
    MOLECULAR THERAPY, 2015, 23 : S259 - S259
  • [47] Influence of interferon (IFN)-based therapy on liver fibrosis progression (LFP) in HIV/HCV co-infected patients
    Benhamou, Yves
    Valentin, Marc Antoine
    Dominguez, Stephanie
    Varastet, Marina
    Zin, Adeline
    Katlama, Christine
    Poynard, Thierry
    HEPATOLOGY, 2007, 46 (04) : 849A - 849A
  • [48] Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
    Mauss, S
    Valenti, W
    DePamphilis, J
    Duff, F
    Cupelli, L
    Passe, S
    Solsky, J
    Torriani, FJ
    Dieterich, D
    Larrey, D
    AIDS, 2004, 18 (13) : F21 - F25
  • [49] Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy
    Kawaguchi, Toshihiro
    Ide, Tatsuya
    Kondo, Reiichiro
    Nomura, Yoriko
    Arinaga-Hino, Teruko
    Kuwahara, Reiichiro
    Amano, Keisuke
    Sano, Tomoya
    Akiba, Jun
    Ohshima, Koichi
    Yano, Hirohisa
    Torimura, Takuji
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (05) : 3991 - 4001
  • [50] Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Arase, Y
    Suzuki, F
    Tsubota, A
    Suzuki, Y
    Saitoh, S
    Kobayashi, M
    Akuta, N
    Someya, T
    Hosaka, T
    Kobayashi, M
    Sezaki, H
    Ikeda, K
    Kumada, H
    INTERVIROLOGY, 2004, 47 (01) : 19 - 25